The Association for Clinical Oncology (Association) is governed by a volunteer Board of Directors, which works to ensure that the Association achieves its mission and vision. Voting Board members are cancer physicians and clinical researchers who volunteer their time. View the Disclosures at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to our COI team.

Association Chair of the Board

Everett E. Vokes, MD, FASCO
View current ASCO disclosure here.

Dr. Vokes is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance (formerly Cancer and Leukemia Group B) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, a member of the Conquer Cancer Development and Fundraising Committee, and a member of the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.

Association Treasurer

Brian Edward Persing, MD
State Affiliate Council Chair

View current ASCO disclosure here.

Dr. Persing received his undergraduate degree in chemistry and his medical degree from the University of South Dakota. He then completed his Internal Medicine residency and Hematology and Oncology Fellowship at the University of Mississippi Medical Center. He entered into private practice on the Mississippi Gulf Coast for 2 years and later joined a hospital-based oncology practice and remained there for 9 years. He became involved in Mississippi Oncology Society (MOS) as a board member and was later voted in as vice president and is currently the president of MOS. Under his guidance, the MOS has established a cancer caucus in Mississippi and MOS is poised financially to aid in supporting advocacy, educational, and legislative efforts across the state. He is currently employed at the University of South Alabama Health (USA) at the Mitchell Cancer Institute as an Assistant Professor of Interdisciplinary Clinical Oncology ultimately being named as interim Program Director for the Oncology Fellowship Program and later the Division Chair of the Department of Hematology and Oncology.   

Association Directors

Lisa A. Carey, MD, FASCO
View current ASCO disclosure here.

Dr. Carey is Deputy Director of Clinical Sciences and the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at the University of North Carolina Lineberger Comprehensive Cancer Center. She is also co-chair of the Alliance cooperative group Breast Committee and a member of the NCI Breast Cancer Steering Committee. Dr. Carey is a member of ASCO’s Breast Cancer Guideline Advisory Group. She previously served the Society as chair of the Nominating Committee, chair of the Professional Development Committee, track leader of the Annual Meeting Education Committee, and a member of the Society’s Audit Committee and the Journal of Clinical Oncology editorial board.

 

Tara O. Henderson, MD, MPH, FASCO
View current ASCO disclosure here.

Dr. Henderson is a professor of pediatrics, Division Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation and director of the Childhood Cancer Survivor Center at the University of Chicago, and co-leader of the cancer prevention and control program for the University of Chicago Comprehensive Cancer Center. She is a graduate of the 2018 President Leadership Scholars program and a 2015 graduate of the ASCO Leadership Development Program. Dr. Henderson is the chair of the ASCO Adolescent and Young Adult (AYA) Survivorship Work Group and a past member of several ASCO committees, including the Government Relations Committee, the Survivorship Guideline Advisory Group, the Conquer Cancer Grants Selection Committee and Osteoporosis in Survivors of Adult Cancers Expert Panel. She is the past chair of the Cancer Survivorship Committee, a member of the Society Board’s Audit Committee and a liaison to the Conquer Cancer Grants Selection Committee.

 

Taofeek K. Owonikoko, MD, PhD, FASCO
View current ASCO disclosure here.

Dr. Owonikoko is the Executive Director of the University of Maryland’s NCI-designated Marlene and Stewart Greenebaum Comprehensive Cancer Center. He is also the Senior Associate Dean of Cancer Programs at the University of Maryland’s School of Medicine and the Associate Vice President of Cancer Programs at the University of Maryland, Baltimore. A translational physician-scientist, board-certified in Medical Oncology, Hematology, and Internal Medicine, he has a clinical focus on the management of patients with lung cancer. His research interests span the spectrum of preclinical experimental therapeutics, biomarker discovery, and translation of promising laboratory findings into lung cancer clinical trials.

He is currently an elected member of the Board of the American Society of Clinical Oncology (ASCO) and the Treasurer-Elect of ASCO. He serves as an Editorial Board Member for several highly regarded academic journals including Cancer, Journal of Thoracic Disease, and Translational Lung Cancer Research. Dr. Owonikoko is a member of the American College of Physicians, American Society for Hematology, the Society for Immunotherapy of Cancer, and the International Association for the Study of Lung Cancer. Lastly, he has been an NIH Study Section Member for the past eleven years and is a chartered member for the NIH Clinical Oncology Study section.

Dr. Owonikoko has authored/co-authored more than 250 peer-reviewed original manuscripts including reports of original research in leading journals such as the New England Journal of Medicine, Lancet, Cell, Science, Nature, JCO, Lancet Oncology, Cancer Discovery, and Cancer Cell. His work has been broadly cited with more than 48,000 citations and an h-index of 86. He has received peer-reviewed extramural grant funding in support of his research from the US National Institutes of Health, Department of Defense, private foundations, and pharmaceutical partners.

 

Elizabeth R. Plimack, MD, MS, FASCO
View current ASCO disclosure here.

Dr. Plimack serves as the Deputy Director of Fox Chase Cancer Center in Philadelphia. She is a professor of medical oncology and the director of genitourinary clinical research at the center. She is a past member and track chair of the ASCO Scientific Program Committee, Genitourinary (Non-Prostate) Cancer track. She serves as a member on the Board’s Audit and Finance Committees and is the Board Liaison to the Cancer Communications Committee. Dr. Plimack is currently the Treasurer of the Society Board of Directors.

 

 

Lynn M. Schuchter, MD, FASCO
View current ASCO disclosure here.

Dr. Schuchter is chief of the Division of Hematology-Oncology at the Abramson Cancer Center at the University of Pennsylvania, director of the Tara Miller Melanoma Center at the Abramson Cancer Center, and the Madlyn and Leonard Abramson Professor of Clinical Oncology at the Perelman School of Medicine of the University of Pennsylvania. Dr. Schuchter is a clinical investigator in the area of melanoma and has a strong commitment to mentorship.  Dr. Schuchter served on the ASCO Board of Directors from 2009 to 2012. She has served on numerous ASCO committees, including terms as chair of Annual Meeting Scientific Program Committee, Cancer Research Committee, and Cancer Communications Committee, and as an editor on the Journal of Clinical Oncology Editorial Board. In 2019, she was recognized with the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award from Conquer Cancer, the ASCO Foundation.

 

Enrique Soto Pérez de Celis, MD, MSc, PhD, FASCO
View current ASCO disclosure here.

Dr. Soto Pérez de Celis is a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City. On the Board, he serves as a liaison to the ASCO Evidence-Based Medicine Commitee, and is a member of the Society’s Finance Committee. He also currently serves on several ASCO committees, including the Journal of Global Oncology Editorial Board, Social Media Working Group, Diversity and Inclusivity Task Force, Technology Research Group, and Publishing Research Group. He has previously served on the AM Education Committee and the Grants Selection Committee. He received a 2019 Conquer Cancer Career Development Award. Previously, Dr. Soto has served on several other ASCO research groups and advisory panels, contributed to the ASCO Connection and ASCO Daily News, and was selected for a Journal of Global Oncology Editorial Fellowship.

 

Piyush Srivastava, MD, FASCO
View current ASCO disclosure here.

Dr. Srivastava is a practicing gastrointestinal oncologist, the physician site leader at Walnut Creek Medical Center, regional medical director of the End of Life Options Program, and director of outpatient palliative care at Kaiser Permanente. He previously Chaired the Clinician Well Being Committee and Clinical Practice Committee and is a past member of the Nominating Committee among other volunteer services.  One of his passions with ASCO is quality; he serves as an ASCO Quality Training Program (QTP) Faculty and Coach. Dr. Srivastava is currently the Chair of the Government Relations Committee.

 

Eric P. Winer, MD, FASCO
View current ASCO disclosure here.  

Dr. Winer is the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven. Before then, he served as the chief clinical development officer, senior vice president for medical affairs, Director of the Dana-Farber/Harvard SPORE in Breast Cancer, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He has also served as a professor of medicine at Harvard Medical School. Dr. Winer served on the ASCO Board of Directors from 2011 to 2015, and has served as chair of the ASCO Government Relations Committee, Cancer Communications Committee, and Health Services Research Committee, among numerous volunteer roles. He was the recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School in 2020. He has also received numerous awards for his breast cancer research, most notably ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture in 2017 and the William L. McGuire Memorial Lecture Award in 2016 at the San Antonio Breast Cancer Symposium.

 

ASCO President-Elect

Robin T. Zon, MD, FACP, FASCO
View current ASCO disclosure here.

Dr. Zon currently serves as the Director of Breast Cancer Oncology at the Cincinnati Cancer Advisors (CCA), a provider of no-cost second opinions to recently diagnosed cancer patients in or near the Greater Cincinnati area. Prior to joining CCA, Dr. Zon served as Past President, and is now Physician Emeritus at Michiana Hematology Oncology in Mishawaka, IN. She formerly served as Medical Director of Oncology Research at Memorial Hospital and NCI CCOP Associate and then Principal Investigator until 2013 for the Northern Indiana Cancer Research Consortium, the only NCI-designated Community Cancer Oncology Program in the state of Indiana. Dr. Zon is an active volunteer for ASCO, most recently being awarded ASCO’s Advocate of the Year for her significant advocacy work on behalf of individuals living with cancer and their cancer care teams, and was the recipient of ASCO’s Distinguished Achievement Award. Dr. Zon is a Past Chair of ASCO’s Government Relations Committee, where she provided distinguished leadership in the society’s advocacy efforts. She also served on the Board of Directors from 2010 to 2013, along with participating in many other ASCO-related responsibilities.

Non-Voting Director - Chief Executive Officer

Clifford A. Hudis, MD, FACP, FASCO
View current ASCO disclosure here.

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice-Chair of its Conquer Cancer Foundation and Chair of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 50,000 members.